{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Stampfer SD"],"funding":["National Institute of Allergy and Infectious Diseases Division of Intramural Research","Emory University School of Medicine","NIAID NIH HHS","National Institutes of Health","NIH HHS","Center for AIDS Research, Emory University","Office of Research Infrastructure Programs"],"pagination":["116501"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12880552"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["44(11)"],"pubmed_abstract":["The 2022 mpox virus (MPXV) outbreak caused life-threatening mpox disease in people living with HIV (PLWH). We compared immune responses to MPXV in PLWH who were either mpox-naive or were mpox survivors. We characterized the magnitude, polyfunctionality, and cytolytic potential of CD4 and CD8 T cells specific to MPXV and cross-reactive orthopoxviral antigens and compared them to HIV- and cytomegalovirus (CMV)-specific T cells. Mpox survivors developed MPXV-specific CD4 T cells capable of producing IFNγ, TNFα, and IL-2. Their polyfunctionality was superior to CMV-specific CD4 T cells. MPXV- and CMV-specific CD8 T cells had similar cytolytic potentials. Importantly, mpox survivors developed strong MPXV-specific antibodies with neutralizing activity. Prior vaccinia or JYNNEOS vaccination was a"],"journal":["Cell reports"],"pubmed_title":["Mpox-specific cellular and humoral immunity in mpox survivors living with HIV."],"pmcid":["PMC12880552"],"funding_grant_id":["P51 OD011132","K08 AI180431","P30 AI050409"],"pubmed_authors":["Amara RR","Sette A","Kelley CF","Stampfer SD","Moriarty M","Gangadhara S","Satheshkumar PS","Priyamvada L","Sheth AN","Sambyal S","Grifoni A"],"additional_accession":[]},"is_claimable":false,"name":"Mpox-specific cellular and humoral immunity in mpox survivors living with HIV.","description":"The 2022 mpox virus (MPXV) outbreak caused life-threatening mpox disease in people living with HIV (PLWH). We compared immune responses to MPXV in PLWH who were either mpox-naive or were mpox survivors. We characterized the magnitude, polyfunctionality, and cytolytic potential of CD4 and CD8 T cells specific to MPXV and cross-reactive orthopoxviral antigens and compared them to HIV- and cytomegalovirus (CMV)-specific T cells. Mpox survivors developed MPXV-specific CD4 T cells capable of producing IFNγ, TNFα, and IL-2. Their polyfunctionality was superior to CMV-specific CD4 T cells. MPXV- and CMV-specific CD8 T cells had similar cytolytic potentials. Importantly, mpox survivors developed strong MPXV-specific antibodies with neutralizing activity. Prior vaccinia or JYNNEOS vaccination was a","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Nov","modification":"2026-07-15T06:59:29.197Z","creation":"2026-06-30T03:35:50.262Z"},"accession":"S-EPMC12880552","cross_references":{"pubmed":["41176764"],"doi":["10.1016/j.celrep.2025.116501"]}}